Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
April 26, 2024
Acurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI at the 16th Biennial Congress of the Anaerobe Society of America
August 2, 2022
Related Post
-
-
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
April 26, 2024
-
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
April 25, 2024
-
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 25, 2024